NKGen to Present Troculeucel NK Cell Therapy Data at China Forum
NKGen Biotech (OTC: NKGN), a clinical-stage biotech company, will present at the 3rd China Great Bay Cell and Gene Therapy Forum in Guangzhou on September 25-26, 2025. CEO Paul Y. Song will discuss their investigational NK cell therapy, troculeucel, for neurodegenerative diseases. The presentation will take place…